Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Detection Firm StageZero Raises C$2.7M

NEW YORK – Cancer detection technology firm StageZero Life Sciences said on Thursday it has raised C$2.7 million ($2.1 million) of its targeted C$3.7 million private placement financing round.

The company, which has offices in Richmond Hill, Ontario, added that it expects the round to close by July 19 and the private placement is fully subscribed.

A total of 42 investors participated in the first closing of the private placement, which is structured as units at C$.115 per unit. Each unit comprises one common share and a half warrant. Each warrant can be exercised for a period of 36 months at $.185.

StageZero develops tests for the early detection of cancer and other diseases in whole blood. Its mRNA-based test called Aristotle screens for 10 cancers — colorectal; prostate; cervical; endometrial; breast; ovarian; liver; bladder; nasopharyngeal; and stomach, according to the company'a website. It added Aristotle is currently undergoing validation.

The firm's College of American Pathologists- and CLIA-certified lab is based in Richmond, Virginia.

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.